-
Circulating ZAG levels were significantly higher in patients with CS than in controls. ZAG levels positively correlated to 24-h urinary free cortisol, body mass index, non-esterified fatty acids, glucose, LDL-C, and type 2 diabetes mellitus, and were inversely related to total adiponectin levels.(p=0.035). In multivariate analysis ZAG levels only correlated with body mass index (p=0.012), type 2 diabetes mellitus.
-
Our study reveals that reduced AZGP1 expression correlates with in vitro cellular migration and invasion. In vivo, it is associated with higher metastatic risk and shorter survival in patients with soft tissue sarcomas
-
results indicate that changes in the circulating level of S100A1 protein occur in metabolic syndrome patients; the strong correlation between serum zinc-alpha2-glycoprotein and S100A1 might suggest that production or release of these two proteins could be related mechanistically
-
Study reports expression of Zinc-alpha2-glycoprotein (ZAG) in neurons. The level of ZAG was lower in temporal lobe epilepsy patients and time-dependently decreased in PTZ-treated rats. In addition, ZAG was shown to interact with p-ERK and TGF-beta. ZAG was found to be synthesized in neurons, and both the AZGP1 mRNA and ZAG protein levels were decreased in epilepsy patients and rat models.
-
Our study provides prospective phase III validation that absent/low AZGP1 expression provides independent prognostic value in PC
-
This study demonstrated that differential expression of zinc-alpha-2-glycoprotein (AZGP1) was detected in the serums of Alzheimer's Disease patients compared with healthy controls
-
ZAG has the potential to alleviate hepatosteatosis, making it a promising therapeutic target for fatty liver.
-
we found that AZGP1 inhibited cell migration and invasion through the regulation of the PTEN/Akt and CD44s pathways. Collectively, our findings revealed the molecular mechanism of AZGP1 expression in HCC, providing new insights into the mechanisms underlying tumor progression.
-
Absent or weak expression of AZGP1 protein was associated with worse recurrence free survival (RFS), disease specific survival, and overall survival after radical prostatectomy for prostate cancer.
-
Absent alpha-2-glycoprotein 1 zinc-binding(AZGP1) expression is an independent predictor of biochemical relapse in margin-positive localized prostate cancer and is associated with increased prostate cancer-specific mortality
-
Data show increased levels of lysozyme C (LYZ), lacritin (LACRT) and zinc-alpha-2 glycoprotein 1 (AZGP1) in pooled tear fluid sample from Graves' disease (GD) patients with moderate-to-severe Graves' orbitopathy (GO) compared with GD patients without clinical signs of GO.
-
From various categories of proteins that have been detected in prostate tissue by proteomics, only secreted protein Zinc alpha 2-glycoprotein showed a clear signal in the urine, proving its discriminative potential for the early diagnosis of prostate cancer
-
results indicate ZAG as a possible predictive marker of Gleason grade. The inverse association between grade and tissue expression with a rising serum protein level is similar to that seen with prostate-specific antigen. In addition, the results for both ZAG and PSMB-6 highlight the challenges in trying to associate the protein levels in serum with tissue expression
-
reduced AZGP1 expression is strongly related to adverse prostate cancer prognosis, independently of established clinic-pathological variables and PTEN deletions.
-
Zinc-alpha2-glycoprotein inhibits insulin-induced glucose uptake in human adipocytes by impairing insulin signaling at the level of AKT in a PP2A-dependent manner.
-
It was concluded that the lipid-binding groove in ZA2G contains at least two distinct fatty acid-binding sites.
-
AZGP1 is a negative regulator of fibrosis progression in kidney and heart
-
Plasma ZAG was elevated in smokers, and correlated with male gender, smoking amount and duration, nicotine dependence, and metabolic syndrome.
-
Increased serum ZAG concentrations induced, at least partly, by Sp1 may cause an increase in vascular tone through the activation of RhoA
-
comprehensive evaluation of AZGP1 variation at the mRNA and protein level in colon cancer; study demonstrated that AZGP1 is a potential serum marker of colon cancer that may be correlated with tumorigenesis
